The annual J.P. Morgan Healthcare Conference “is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community” (JPMorgan.com).
This year’s conference covered a wide range of trends in healthcare, from anticipated topics like drug pricing reform, to repeat themes with an unexpected twist (where’s all of the M&A activity?), and everything in between.
In case you missed it, we put together a summary of the top news headlines and best social media commentary capturing the biggest takeaways from JPM 2020.
Big Pharma CEOs Weigh In On Drug Prices At JPM 2020: CNBC
Analysis: Pharma Executives Address Drug Prices At JPM 2020 As Political Pressure For Reform Builds: Barron’s
Drugmakers Exploring New Methods Of Payment For Expensive Medicines: Wall Street Journal
Pharma Dealmaking Slows At This Year’s JP Morgan Healthcare Conference, Executives Say: FiercePharma
Lack Of Large Deals Seen As Top Theme At JP Morgan Healthcare Conference So Far: STAT
The Next Therapeutic Area of Major Innovation?
Neuroscience Field Poised For Drug Development Innovation, Karuna CEO Says: FierceBiotech
Roche Sees Growing Role For Neuroscience This Decade: BioPharma Dive
JPM 2020 Attendees Wary Of Vague “Digital Health” Definition, Address Drug Pricing: CNBC
Drug Launch Strategies
Novartis Executives Discuss Drug Launch Strategies: FiercePharma
Merck CEO Ken Frazier Highlights Keytruda Success, Drug Price Challenges, And More: Fox Business
Year of the Consumer
JPM’s Lisa Gill Says Conference Is Focused On The “Year Of The Consumer:” CNBC’s Mad Money
Social Media Commentary
1. @Chrissyfarr on her top 5 takeaways from #JPM20.
— Christina Farr (@chrissyfarr) January 15, 2020
2. @jacqueline_says on the current status of digital health.
#jpm20: @chrissyfarr + @AmerMedicalAssn discuss evidence-based care. There are 300k #mhealth apps, 40k which are patient-facing. Out of the 150 deemed the “best”, most weren’t even usable, the AMA tells Chrissy. #JPMorgan2020 #JPM2020 #AI #DigitalHealth pic.twitter.com/hvqY2fqxuD
— Jacqueline DiChiara (@jacqueline_says) January 14, 2020
3. @AndyBiotech on the “lack of M&A at #JPM20.”
This is probably the most interesting stat in 2020 E&Y Firepower Report and explains the lack of M&A at #JPM20
— Andy Biotech (@AndyBiotech) January 15, 2020
4. @MariaBartiromo on pharma research investments.
— Maria Bartiromo (@MariaBartiromo) January 14, 2020
5. @Chrissyfarr on unanimous opinions about “health data interoperability.”
2020 is the year we will see some movement on health data interoperability.
— Christina Farr (@chrissyfarr) January 16, 2020